When Private Insurance Buys Faster Access to Public Care

Why It Matters

The findings reveal that private supplemental insurance can deepen inequities and increase public spending, challenging the notion that it relieves pressure on universal systems. Policymakers must address the regressive cost burden and queue distortion it creates.

Key Takeaways

• Supplemental insurance enrollment ranges from <5% low-income to ~50% high-income.
• SHI raises total healthcare spending by ~23%, especially for low earners.
• Two‑thirds of extra SHI spending is still publicly financed.
• Waiting times for public care drop ~7 days after SHI enrollment.
• Early cancer detection improves, but overall mortality impact remains small.

Pulse Analysis

Universal health coverage across Europe has largely succeeded in guaranteeing basic access, yet the new bottleneck is timeliness. As populations age and health‑care workforces thin, waiting lists have lengthened, prompting many workers to seek employer‑provided supplemental health insurance (SHI). This private layer promises faster specialist visits, diagnostics, and elective procedures, and its penetration varies widely—from about 15% in France and the UK to over 50% in Australia and Denmark. Sweden’s rapid SHI growth, now covering roughly 15% of the working‑age population, offers a microcosm for studying how private add‑ons interact with public queues.

The recent Swedish analysis links SHI contracts to nationwide health‑care utilization data, revealing that SHI users experience a 23% jump in total health spending, driven largely by increased hospital admissions and prescription use. Crucially, the spending surge is not confined to the private sector; about two‑thirds of the extra costs flow back into publicly funded care because patients often start with private consultations and then re‑enter the public system for advanced treatment. This dynamic shortens public waiting times by roughly seven days—benefiting insured patients but potentially extending queues for the uninsured. The benefits are most pronounced for lower‑income workers, whose health spending rises over 50%, and for cancer care, where earlier detection improves outcomes despite negligible effects on overall mortality.

Policy implications are stark. While SHI can deliver valuable care faster, its concentration among higher‑income employees makes the net effect regressive: low‑income individuals bear part of the $130 per‑person fiscal and congestion externalities without enjoying the speed advantage. A simple welfare calculation estimates the private value of SHI at about $220 per enrollee annually, suggesting that the public sector subsidizes a sizable share of the benefit. Regulators must therefore consider mechanisms—such as risk‑adjusted subsidies or caps on private referrals—to prevent two‑tiered access and ensure that universal systems continue to allocate care by medical need rather than ability to pay.